{"title":"Developments in the Management of Type 1 and Type 2 Diabetes.","authors":"Chantal Mathieu","doi":"10.17925/EE.2018.14.2.13","DOIUrl":null,"url":null,"abstract":"Received: 10 July 2018 Published Online: 17 July 2018 Citation: European Endocrinology. 2018;14(2):13–4 Corresponding Author: Chantal Mathieu, Dept Endocrinology UZ Gasthuisberg Herestraat 49 3000 Leuven, Belgium. E: chantal.mathieu@uzleuven.be Poor glucose control resulting from diabetes is responsible for the deaths of millions of people worldwide each year, and reduces the quality of life for many more. As a result, research continues for new glucose-lowering drugs, as well as improved ways to manufacture and deliver insulin. In this expert interview, Chantal Mathieu, Professor of Medicine at the Catholic University of Leuven, Belgium, discusses some of the latest developments in the management of both type 1 (T1D) and type 2 (T2D) diabetes.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"14 2","pages":"13-14"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/fb/euendo-14-13.PMC6182930.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/EE.2018.14.2.13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/9/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1
Abstract
Received: 10 July 2018 Published Online: 17 July 2018 Citation: European Endocrinology. 2018;14(2):13–4 Corresponding Author: Chantal Mathieu, Dept Endocrinology UZ Gasthuisberg Herestraat 49 3000 Leuven, Belgium. E: chantal.mathieu@uzleuven.be Poor glucose control resulting from diabetes is responsible for the deaths of millions of people worldwide each year, and reduces the quality of life for many more. As a result, research continues for new glucose-lowering drugs, as well as improved ways to manufacture and deliver insulin. In this expert interview, Chantal Mathieu, Professor of Medicine at the Catholic University of Leuven, Belgium, discusses some of the latest developments in the management of both type 1 (T1D) and type 2 (T2D) diabetes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
